薬学の世界

18 Labs

薬の効き方 薬効解析学研究室

学会発表

β-クリプトキサンチン摂取による破骨細胞活性化抑制を介した閉経後骨粗鬆症の予防効果
大西 勇気, 岡本 舞香, 尾崎 翔, 深澤 和也, 米田 幸雄, 金田 勝幸, 杉浦 実, 檜井 栄一
日本薬学会第136年会  2016年3月

β-クリプトキサンチン摂取は卵巣摘出マウスにおける破骨細胞活性化と骨量減少を防ぐ
大西 勇気, 岡本 舞香, 尾崎 翔, 深澤 和也, 米田 幸雄, 金田 勝幸, 杉浦 実, 檜井 栄一
第89回日本薬理学会年会  2016年3月

β-クリプトキサンチンは閉経後骨粗鬆症の発症を抑制する
大西 勇気, 岡本 舞香, 尾崎 翔, 深澤和也, 米田 幸雄, 金田 勝幸, 杉浦 実, 檜井 栄一
第128回日本薬理学会近畿部会  2015年11月

β-クリプトキサンチン摂取による骨粗鬆症の予防及び治療効果の検討
大西 勇気, 岡本 舞香, 尾崎 翔, 深澤和也, 米田 幸雄, 金田 勝幸, 杉浦 実, 檜井 栄一
日本薬学会北陸支部第127回例会  2015年11月

マウス海馬歯状回門におけるGABAB受容体を発現する星状膠細胞の増加
大西 勇気, 山村 祐介, 細木 美沙, 荻田 喜代一, 倉本 展行
日本薬学会第134年会  2014年3月

神経再生時のマウス海馬歯状回門におけるGABAB受容体発現アストロサイト
大西 勇気, 細木 美沙, 倉本 展行
第125回日本薬理学会近畿部会  2014年6月

マウス海馬歯状回における神経新生とGABAB受容体発現量の増加との関連性
大西 勇気, 山村 祐介, 細木 美沙, 荻田 喜代一, 倉本 展行
第36回日本分子生物学会年会  2013年12月

マウス海馬歯状回における神経組織の新生とGABAB受容体発現量の増加との関連性
大西 勇気, 山村 祐介, 細木 美沙, 荻田 喜代一, 倉本 展行
第63回日本薬学会近畿支部  2013年10月

学術論文

Hypoxia affects Slc7a5 expression through HIF-2α in differentiated neuronal cells.
Onishi Y, Hiraiwa M, Kamada H, Iezaki T, Yamada T, Kaneda K, Hinoi E
FEBS open bio 9(2) 241-247 Feb 2019

The MAPK Erk5 is necessary for proper skeletogenesis involving a Smurf-Smad-Sox9 molecular axis.
Iezaki T, Fukasawa K, Horie T, Park G, Robinson S, Nakaya M, Fujita H, Onishi Y, Ozaki K, Kanayama T, Hiraiwa M, Kitaguchi Y, Kaneda K, Yoneda Y, Takarada T, Guo XE, Kurose H, Hinoi E
Development (Cambridge, England) 145(14) Jul 2018

Translational Control of Sox9 RNA by mTORC1 Contributes to Skeletogenesis.
Iezaki T, Horie T, Fukasawa K, Kitabatake M, Nakamura Y, Park G, Onishi Y, Ozaki K, Kanayama T, Hiraiwa M, Kitaguchi Y, Kaneda K, Manabe T, Ishigaki Y, Ohno M, Hinoi E
Stem cell reports 11(1) 228-241 Jul 2018

Hypoxic Stress Upregulates the Expression of Slc38a1 in Brown Adipocytes via Hypoxia-Inducible Factor-1α.
Horie T, Fukasawa K, Iezaki T, Park G, Onishi Y, Ozaki K, Kanayama T, Hiraiwa M, Kitaguchi Y, Kaneda K, Hinoi E
Pharmacology 101(1-2) 64-71  2018

Daily oral intake of β-cryptoxanthin ameliorates neuropathic pain.
Park G, Horie T, Iezaki T, Okamoto M, Fukasawa K, Kanayama T, Ozaki K, Onishi Y, Sugiura M, Hinoi E
Bioscience, biotechnology, and biochemistry 81(5) 1014-1017 May 2017

The transcriptional modulator Ifrd1 controls PGC-1α expression under short-term adrenergic stimulation in brown adipocytes.
Park G, Horie T, Kanayama T, Fukasawa K, Iezaki T, Onishi Y, Ozaki K, Nakamura Y, Yoneda Y, Takarada T, Hinoi E
The FEBS journal 284(5) 784-795 Mar 2017

The transcriptional modulator Ifrd1 is a negative regulator of BMP-2-dependent osteoblastogenesis.
Onishi Y, Park G, Iezaki T, Horie T, Kanayama T, Fukasawa K, Ozaki K, Hinoi E
Biochemical and biophysical research communications 482(2) 329-334 Jan 2017

Amelioration of the Development of Osteoarthritis by Daily Intake of β-Cryptoxanthin.
Park G, Horie T, Fukasawa K, Ozaki K, Onishi Y, Kanayama T, Iezaki T, Kaneda K, Sugiura M, Hinoi E
Biological & pharmaceutical bulletin 40(7) 1116-1120  2017

Transcriptional Modulator Ifrd1 Regulates Osteoclast Differentiation through Enhancing the NF-κB/NFATc1 Pathway.
Iezaki T, Fukasawa K, Park G, Horie T, Kanayama T, Ozaki K, Onishi Y, Takahata Y, Nakamura Y, Takarada T, Yoneda Y, Nakamura T, Vacher J, Hinoi E
Molecular and cellular biology 36(19) 2451-2463 Oct 2016

ATF3 deficiency in chondrocytes alleviates osteoarthritis development.
Iezaki T, Ozaki K, Fukasawa K, Inoue M, Kitajima S, Muneta T, Takeda S, Fujita H, Onishi Y, Horie T, Yoneda Y, Takarada T, Hinoi E
The Journal of pathology 239(4) 426-437 Aug 2016

ATF3 controls proliferation of osteoclast precursor and bone remodeling.
Fukasawa K, Park G, Iezaki T, Horie T, Kanayama T, Ozaki K, Onishi Y, Takahata Y, Yoneda Y, Takarada T, Kitajima S, Vacher J, Hinoi E
Scientific reports 6 30918 Aug 2016

The Transcriptional Modulator Interferon-Related Developmental Regulator 1 in Osteoblasts Suppresses Bone Formation and Promotes Bone Resorption.
Iezaki T, Onishi Y, Ozaki K, Fukasawa K, Takahata Y, Nakamura Y, Fujikawa K, Takarada T, Yoneda Y, Yamashita Y, Shioi G, Hinoi E
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 31(3) 573-584 Mar 2016

GDF1 is a novel mediator of macrophage infiltration in brown adipose tissue of obese mice.
Onishi Y, Fukasawa K, Ozaki K, Iezaki T, Yoneda Y, Hinoi E
Biochemistry and biophysics reports 5 216-223 Mar 2016

Overexpression of BCLXL in Osteoblasts Inhibits Osteoblast Apoptosis and Increases Bone Volume and Strength.
Moriishi T, Fukuyama R, Miyazaki T, Furuichi T, Ito M, Komori T.
J Bone Miner Res. 2016 Feb 8. doi: 10.1002/jbmr.2808. [Epub ahead of print]

Daily intake of β-cryptoxanthin prevents bone loss by preferential disturbance of osteoclastic activation in ovariectomized mice.
Ozaki K, Okamoto M, Fukasawa K, Iezaki T, Onishi Y, Yoneda Y, Sugiura M, Hinoi E
Journal of pharmacological sciences 129(1) 72-77 Sep 2015

Dephosphorylation of endogenous GABA(B) receptor R2 subunit and AMPK α subunits which were measured by in vitro method using transfer membrane.
Kuramoto N, Ito M, Saito Y, Niihara H, Tanaka N, Yamada K, Yamamura Y, Iwasaki K, Onishi Y, Ogita K
Neurochemistry international 62(2) 137-144 Jan 2013

Pyruvate dehydrogenase kinase 4 induces bone loss at unloading by promoting osteoclastogenesis.
Wang Y, Liu W, Masuyama R, Fukuyama R, Ito M, Zhang Q, Komori H, Murakami T, Moriishi T, Miyazaki T, Kitazawa R, Yoshida CA, Kawai Y, Izumi S, Komori T.
Bone. 2012 Jan;50(1):409-19.

SP7 inhibits osteoblast differentiation at a late stage in mice.
Yoshida CA, Komori H, Maruyama Z, Miyazaki T, Kawasaki K, Furuichi T, Fukuyama R, Mori M, Yamana K, Nakamura K, Liu W, Toyosawa S, Moriishi T, Kawaguchi H, Takada K, Komori T.
PLoS One. 2012;7(3):e32364. doi: 10.1371/journal.pone.0032364. Epub 2012 Mar 2.

Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.
Moriishi T, Fukuyama R, Ito M, Miyazaki T, Maeno T, Kawai Y, Komori H, Komori T.
PLoS One. 2012;7(6):e40143. doi: 10.1371/journal.pone.0040143. Epub 2012 Jun 29.

Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis.
Moriishi T, Maruyama Z, Fukuyama R, Ito M, Miyazaki T, Kitaura H, Ohnishi H, Furuichi T, Kawai Y, Masuyama R, Komori H, Takada K, Kawaguchi H, Komori T.
PLoS One. 2011;6(11):e27487. doi: 10.1371/journal.pone.0027487. Epub 2011 Nov 17.

Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats.
Fujita M, Ohnishi K, Takaoka S, Ogasawara K, Fukuyama R, Nakamuta H.
Biol Pharm Bull. 2011;34(11):1696-701.

Anti-osteoporosis effect of 5-bromo-2-(4-chlorobenzoyl)-(Z)-3-(2-cyano-3-hydroxybut-2-enonyl)aminobenzo[b]furan: a novel selective estrogen receptor modulator.
Fukuyama R, Shimokawa A, Kodama Y, Fujita M, Ohishi Y, Ando Y, Koida M, Nakamuta H.
J Pharmacol Sci. 2011;116(2):214-20. Epub 2011 May 21.

Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency.
Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, Fukuyama R, Miyazaki T, Kitaura H, Nakamura K, Fujita T, Kanatani N, Moriishi T, Yamana K, Liu W, Kawaguchi H, Nakamura K, Komori T.
Dev Dyn. 2007 Jul;236(7):1876-90.

Cbf beta regulates Runx2 function isoform-dependently in postnatal bone development.
Kanatani N, Fujita T, Fukuyama R, Liu W, Yoshida CA, Moriishi T, Yamana K, Miyazaki T, Toyosawa S, Komori T.
Dev Biol. 2006 Aug 1;296(1):48-61. Epub 2006 Apr 4.
ページのトップへ戻る